Abstract
Understanding various subpopulations in chronic kidney disease can improve patient care and aid in developing treatments targeted to patients’ needs. Due to the general slow disease progression, electronic health records, which comprise a rich source of longitudinal real-world patient-level information, offer an approach for generating insights into disease. Here we apply the open-source ConvAE framework to train an unsupervised deep learning network using a real-world kidney disease cohort consisting of 2.2 million US patients from the OPTUM® EHR database. Numerical patient representations derived from ConvAE are used to derive disease subtypes, inform comorbidities and understand rare disease populations. To identify patients at high risk to develop end-stage kidney disease, we extend a validated algorithm classifying disease severity to hypothesize subpopulations of rapid chronic kidney disease progressors. We demonstrate that using a combination of data-driven methods offers a powerful exploratory approach to understand disease heterogeneity and identify high-risk patients who could be targeted for early therapeutic intervention to prevent end-stage kidney disease.
Competing Interest Statement
Mixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KK, MF and MR were employed by Novartis at the time the submitted work was produced; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used de-identified electronic health record data available from OPTUM. https://www.optum.com/business/life-sciences/real-world-data/ehr-data.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
